Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.
Fiche publication
Date publication
juin 2020
Journal
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ABELY Michel
Tous les auteurs :
Burgel PR, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Biouhee T, Hubert D, Munck A, Lemonnier L, Dehillotte C, Silva JD, Paillasseur JL, Martin C,
Lien Pubmed
Résumé
Phase 3 trials have demonstrated the safety and efficacy of lumacaftor-ivacaftor (LUMA-IVA) in patients with cystic fibrosis (CF) homozygous for the Phe508del CFTR mutation and percent predicted forced expiratory volume in 1 s (ppFEV) between 40 and 90. Marketing authorizations have been granted for patients at all levels of ppFEV.
Référence
J. Cyst. Fibros.. 2020 Jun 23;: